NewsRoom Articles - Page 33 of 214

TuesdayJul 30, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials

Annovis announced in June 2024 that they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process The company’s goal is to use this technology to restore brain function and improve the quality of life for patients dealing with neurodegenerative disease such as Alzheimer’s disease The worldwide market for Alzheimer’s disease modifying drugs, versus symptomatic drugs, could approach $30 billion by 2030 Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s, just announced that the U.S.…

MondayJul 29, 2024 10:00 am

Researchers Identify New Gene Behind ALS Onset

Scientists have discovered a new mutation that may cause amyotrophic lateral sclerosis to develop. Amyotrophic lateral sclerosis, or ALS in short, is a neurodegenerative illness that weakens an individual’s muscles and affects their physical function. It starts by degenerating nerve cells in the brain and spinal cord, affecting an individual’s voluntary control of legs and arms. The illness leads to trouble breathing, swallowing and may cause slurred speech. The illness is rare, with an average incidence of 1.4 to 2.4 cases in every 100,000 individuals annually. Additionally, the illness, which is sometimes referred to as motor neuron disease, has no…

FridayJul 26, 2024 10:00 am

Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans

New research has highlighted the increased risk of illnesses spreading to humans from animals. The report by researchers from New York University and Harvard Law School examined common interactions between humans and animals in 15 countries, including the United States. The researchers discovered numerous examples where viruses could spread to humans, explaining that while zoonotic illnesses, including monkeypox and smallpox, had always existed, their prevalence was growing as interactions between animals and humans increased with urban expansion, climate shifts and international travel. In their report, the researchers noted that changes in policy could greatly decrease the risk of illness crossover.…

FridayJul 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast

Clene’s mission is to transform the treatment of neurodegenerative diseases with a new class of drugs, potentially impacting the lives of millions The company’s uniquely structured gold nanocrystals have the remarkable ability to convert critical energetic metabolites in living cells for the production of ATP, the essential energy currency for cellular functions, offering disease combatting capabilities Clene is currently preparing for Phase 3 clinical trials of CNM-Au8for ALS and MS, following successful early studies Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial…

ThursdayJul 25, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Treatments for Underserved Neurological Disorders

PaxMedica is preparing to submit a New Drug Application to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis On June 27th, PaxMedica will have a Type C meeting with the FDA, pivotal for the progress of PAX-101, their leading drug candidate for autism treatment, within the regulatory framework The outcomes of this FDA meeting are crucial, representing a key moment for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101 The global ASD therapeutics market is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, driven by increasing…

WednesdayJul 24, 2024 10:00 am

Prime Day 2024 Is Massive Success for Amazon as American Buyers Spend $14B-Plus

July 16, 2024, marked the beginning of this year’s Amazon Prime Day, which established a new record in online shopping. The annual two-day sale, which ended on July 17, saw consumers in America spend more than $14 billion. This year’s figure represents an 11% rise in consumer spending, as 2023’s total consumer spending stood at $12.7 billion. On the first day of the sale, $7.2 billion was spent by consumers. During the same period in 2023, consumers spent 11.2% less. The momentum grew on day two of the sale, with consumer spending hitting $7 billion. Amazon released a statement confirming…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

TuesdayJul 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join…

TuesdayJul 23, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative…

MondayJul 22, 2024 10:00 am

Study Uncovers Ancient Egyptian Attempts to Surgically Remove Brain Cancer

New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant tumors. The researchers found that one skull, which belonged to a female about 50 years of age, had healed injuries on the cranium that may have been made by a sharp object. This evidence suggests that the woman survived because of a treatment and some post-traumatic care administered. Another skull, belonging to a man in his 30s, also had…